Changeflow GovPing Healthcare & Life Sciences Royal Emerald Pharma DEA Controlled Substances ...
Routine Notice Added Final

Royal Emerald Pharma DEA Controlled Substances Application

Email

Summary

The Drug Enforcement Administration published notice that Royal Emerald Pharmaceuticals, 14011 Palm Drive, Building B, Desert Hot Springs, California 92240-6845, applied on March 3, 2026 to be registered as an importer of three Schedule I controlled substance basic classes: Marihuana Extract (7350), Marihuana (7360), and Tetrahydrocannabinols (7370). The company plans to import immature plants for continued cultivation under its Bulk Manufacturing registration. Registered bulk manufacturers and applicants may submit electronic comments or written hearing requests on or before May 18, 2026.

“Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before May 18, 2026.”

DEA , verbatim from source
Published by DEA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors Regs.gov: Drug Enforcement Administration for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 30 changes logged to date.

What changed

DEA published notice of Royal Emerald Pharmaceuticals' March 3, 2026 application to register as an importer of three Schedule I controlled substances: Marihuana Extract (7350), Marihuana (7360), and Tetrahydrocannabinols (7370). The company seeks to import immature marijuana plants as starting materials for botanical raw materials and Active Pharmaceutical Ingredients under its existing Bulk Manufacturing registration. Registered bulk manufacturers of the affected basic classes and other interested parties may file electronic comments or written hearing requests by May 18, 2026.

Pharmaceutical manufacturers and researchers working with Schedule I controlled substances should note this application as it may affect market dynamics for marijuana-derived starting materials. Competitors and industry stakeholders have a 30-day window to file objections or request a hearing before the DEA considers the registration.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

ACTION:

Notice of application.

SUMMARY:

Royal Emerald Pharmaceuticals has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer
to
SUPPLEMENTARY INFORMATION
listed below for further drug information.

DATES:

Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on
or objections to the issuance of the proposed registration on or before May 18, 2026. Such persons may also file a written
request for a hearing on the application on or before May 18, 2026.

ADDRESSES:

The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file
for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive
a Comment Tracking Number. Please be

aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit
the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ,
8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration,
Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION:

In accordance with 21 CFR 1301.34(a), this is notice that on March 3, 2026, Royal Emerald Pharmaceuticals, 14011 Palm Drive,
Building B, Desert Hot Springs, California 92240-6845, applied to be registered as an importer of the following basic class(es)
of controlled substance(s):

Controlled substance Drug code Schedule
Marihuana Extract 7350 I
Marihuana 7360 I
Tetrahydrocannabinols 7370 I

The company plans to import immature plants to use as starting/raw materials to continue cultivation of Marihuana under their
Bulk Manufacturing registration. All products and materials will be developed as botanical raw materials or Active Pharmaceutical
Ingredients for Drug Enforcement Administration-approved legitimate medical, scientific, research, and/or industrial purposes.
No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved
finished dosage forms for commercial sale.

Thomas Prevoznik, Deputy Assistant Administrator. [FR Doc. 2026-07561 Filed 4-16-26; 8:45 am] BILLING CODE 4410-09-P

Download File

Download

CFR references

21 CFR 1301.34(a)

Get daily alerts for Regs.gov: Drug Enforcement Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from DEA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
DEA
Comment period closes
May 18th, 2026 (25 days)
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
DEA-2026-0666

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Controlled substance import Importer registration
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Topics
Cannabis

Get alerts for this source

We'll email you when Regs.gov: Drug Enforcement Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!